Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04395183 · ClinicalTrials.gov registry record · Phase 2

5-HTP and Creatine for Depression

A Phase 2 study, sponsored by University of Utah.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target

NCT04395183 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 43 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04395183, a Phase 2 study, has completed, sponsored by University of Utah.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target

Study Summary

This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP + placebo, creatine + placebo, and 5-HTP + creatine, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.

Interventions

  • DRUG Placebo
  • DRUG Creatine monohydrate
  • DRUG 5-Hydroxytryptophan 100 MG
  • DRUG placebo matched to 5-HTP

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2021-03-01
Est. Completion 2024-03-01
Phase Phase 2

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT04395183

The ClinicalTrials.gov registry entry for NCT04395183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT04395183 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04395183 about?

NCT04395183 is a clinical study titled "5-HTP and Creatine for Depression". This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP + placebo, creatine + placebo, and 5-HTP + creatine, for 8 weeks. The ability of the interventions...

What is the current status of trial NCT04395183?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2021-03-01. Estimated completion is 2024-03-01.

What interventions are being tested in trial NCT04395183?

The interventions under investigation include: Placebo (DRUG), Creatine monohydrate (DRUG), 5-Hydroxytryptophan 100 MG (DRUG), placebo matched to 5-HTP (DRUG).

Who is sponsoring clinical trial NCT04395183?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.